Recap: Exelixis Q4 Earnings

Exelixis (NASDAQ:EXEL) reported its Q4 earnings results on Tuesday, February 6, 2024 at 04:05 PM. Here’s what investors…

Exelixis (NASDAQ:EXEL) reported its Q4 earnings results on Tuesday, February 6, 2024 at 04:05 PM.

Here’s what investors need to know about the announcement.

Earnings

Exelixis beat estimated earnings by 50.0%, reporting an EPS of $0.33 versus an estimate of $0.22.

Revenue was up $55.73 million from the same period last year.

Past Earnings Performance

Last quarter the company missed on EPS by $0.05 which was followed by a 4.23% drop in the share price the next day.

Here’s a look at Exelixis’s past performance:

Quarter Q3 2023 Q2 2023 Q1 2023 Q4 2022
EPS Estimate 0.15 0.22 0.15 -0.12
EPS Actual 0.10 0.31 0.16 -0.03
Revenue Estimate 472.21M 450.07M 424.10M 417.50M
Revenue Actual 471.92M 469.85M 408.79M 423.92M

To track all earnings releases for Exelixis visit their earnings calendar here.

This article was generated by Benzinga’s automated content engine and reviewed by an editor.

Total
0
Shares
Related Posts
Read More

Acreage’s Q1 Revenue Slips 19% YoY But CEO Foresees ‘Significant Growth Opportunities’ As Canopy Growth Strategy Moves Forward

Multi-state cannabis operator Acreage Holdings, Inc. (CSE: ACRG.A.U, ACRG.B.U) (OTCQX: ACRHF, ACRDF), reported on Friday its financial results for the first quarter ended March 31, 2024. "In the first quarter, we diligently focused on cash preservation, implementing cost-saving measures, and honing our business strategy," Dennis Curran, the company's CEO, said. "Our Northeastern footprint was a focal point with our entry into the New York adult-use wholesale market and the conversion of our third dispensary in Connecticut to a hybrid model serving both patients and consumers."

ACRDF